Troxatyl
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
BackgroundGemcitabine, a deoxycytidine nucleoside analog, is the current standard chemotherapy used as first-line treatment for…
Abstract Troxacitabine (Troxatyl; BCH-4556; (–)-2′-deoxy-3′-oxacytadine) is the first synthetic L-nucleoside enantiomer to…
BACKGROUND
Troxacitabine (Troxatyl) is a novel L-enantiomer nucleoside analog with activity in pancreatic cancer xenograft models…
The application of structural biology as a starting point for drug development is now maturing as recent development in the…
PURPOSE
A multi-institution phase II study was undertaken by National Cancer Institute of Canada-Clinical Trials Group to…
PurposeTroxacitabine (BCH-4556, l-(−)-OddC, Troxatyl) is a novel β-l-nucleoside analogue with potent antineoplastic activity both…
Abstract
Purpose. We have recently identified a deoxycytidine nucleoside analogue, troxacitabine (β-L-dioxolane cytidine…
PURPOSE
Troxacitabine (Troxatyl, BCH-4556; BioChem Pharma Inc, Basingstoke, United Kingdom) is a novel synthetic L-nucleoside…
Unique among currently approved or in-development nucleoside analogs, troxacitabine (Troxatyl™) is an L-nucleoside with…
Abstract.Purpose: Troxacitabine (β-L-dioxolane cytidine, BCH-4556; Troxatyl, BioChem Pharma Inc.) is a novel nucleoside analogue…